Most Read Articles
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).

Amoxicillin-clavulanate regimen for PBB: 4 weeks no better than 2 weeks

Roshini Claire Anthony
28 Sep 2020

A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.

“Four weeks of antibiotics vs 2 weeks had no effect on cough resolution at 28 days. However, 4 weeks of antibiotics is associated with increased time to next wet cough exacerbation,” presented Dr Tom Ruffles from The Royal Alexandra Children’s Hospital in Brighton, UK, at ERS 2020.

The study population comprised 106 children aged 2 months to 19 years (median age 2 years) with suspected PBB. They were randomized to receive twice-daily doses of amoxicillin-clavulanate (reconstituted to 400 mg/57 mg/5 mL and dosed at 25–35 mg/kg/dose) for either 4 weeks or 2 weeks followed by a 2-week period on placebo. Compared with children in the 2-week group, those in the 4-week group had a longer duration of cough (21.4 vs 13.0 weeks) and lower use of antibiotics for current cough at enrolment.

At day 28, clinical cure, defined as cough resolution for 2 days or >75 percent improvement from baseline (over 3 days) in cough scores, did not significantly differ between children who received the 4-week and 2-week amoxicillin-clavulanate regimen (61.5 percent vs 70.4 percent; adjusted risk ratio, 0.87, 95 percent confidence interval [CI], 0.60–1.28; p=0.49). [ERS 2020, presentation Nr4131]

Among those whose coughs resolved by 28 days (n=70), recurrence of PBB wet cough at 6 months also did not differ between the 4-week and 2-week group (53.1 percent vs 73.4 percent; adjusted odds ratio [adjOR], 0.39, 95 percent CI, 0.14–1.04; p=0.07).

Number of exacerbations did not significantly differ between the 4-week and 2-week group (mean 1.06 vs 1.13; adjOR, 0.24, 95 percent CI, 0.58–1.41; p=0.66). However, time to first cough exacerbation was significantly longer with the 4-week vs 2-week regimen (150 vs 35.5 days; adjusted hazard ratio, 0.47, 95 percent CI, 0.25–0.90; p=0.02). 

“PBB is defined clinically as a chronic wet cough greater than 4 weeks duration without signs or symptoms of another cause that responds to an appropriate 2- to 4-week course of antibiotics,” explained Ruffles.

“However, there is little consensus with respect to the optimal duration of antibiotic treatment for PBB,” he said, noting the different recommendations as stated in the British Thoracic Society and the American College of Chest Physicians guidelines (4- to 6-week and 2-week initial course, respectively). [Thorax 2008;63(Suppl III):iii1-iii15; Chest 2020;158:303-329]

“[In this study,] longer duration of antibiotics was associated with a fourfold increase in the time to next wet cough exacerbation,” Ruffles pointed out. However, randomized controlled trials are warranted to determine the optimal duration of antibiotic treatment for PBB in children, as well as a potential subgroup that may benefit from longer regimens.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).